Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journalon June 24, 2022 at 6:00 am
IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched ...
- The Week Unwrapped: Immunotherapy, unions and a house revivalon June 24, 2022 at 5:51 am
Have unions finally cracked the tech sector? And is 90s house music making a comeback? Olly Mann and The Week delve behind the headlines and debate what really matters from the past seven days. You ...
- Dana-Farber CEO answers questions on cancer treatment, researchon June 24, 2022 at 3:00 am
Dana-Farber was named the fourth best hospital in the country for cancer by the U.S. News and World Report, and according to Glimcher, is the top academic recipient of grant funding from the National ...
- Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLCon June 23, 2022 at 5:03 am
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology Clinical and ...
- The Worldwide Combination Cancer Immunotherapy Industry Is Expected To Surpass $15 Billion By 2028on June 23, 2022 at 3:38 am
The 'Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028' report has been added to ResearchAndMarkets.com's offering. As per report findings, the global ...
- Global Combination Cancer Immunotherapy Market Opportunities to 2028 - Featuring Abbvie, Amgen and Eli Lilly Among Others - ResearchAndMarkets.comon June 23, 2022 at 3:06 am
The “Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028” report has been added to ResearchAndMarkets.com’s offering. As per report findings, the global ...
- Cancer patients receiving immunotherapy: No evidence of increased risk for severe immune complication after COVID-19 vaccinationon June 22, 2022 at 5:00 pm
Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A ...
- Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Canceron June 22, 2022 at 10:00 am
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomeson June 19, 2022 at 10:00 am
The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.
- Immunotherapy booster produces 10,000 times more cancer-fighting cellson June 16, 2022 at 8:21 pm
Researchers at Washington University in St. Louis have found that adding a booster protein can significantly improve the outcome of cancer immunotherapy. Tests in mice showed the protein produced ...
via Bing News